Sanofi news
The WiseView Research desk's stories that name Sanofi, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The SNY page →
- HeadlineRegeneron's Billion-Dollar Catalyst Flying Under Wall Street's Radar Ahead of Oct. 30 Earnings
- HeadlineSanofi: An Alluring And Balanced Mix Of Yield And Growth
- Company earningsThermo Fisher Scientific tops Q3 estimates, but shares slide premarket
Thermo Fisher beat EPS and revenue estimates for Q3, yet the stock fell before the open on October 21, 2026.
- HeadlineSanofi: Why The Market Seems To Be Overpricing Pipeline Risk
- HeadlineEnable Injections Announces Approval in Japan for CirCLIQ® Injector based on enFuse® On-Body Delivery System
- HeadlinePress Release: Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany
- HeadlineRecursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
- HeadlineWhich Pharma Stock Looks More Attractive: Sanofi or AbbVie?
- HeadlineEU Accepts Sanofi's Concessions to Settle Antitrust Probe Over Vaccine Marketing
- HeadlinePress Release : Availability of the aide-mémoire for Q3 2026 results
- HeadlineAs First Dupixent MDL Hearing Opens, Weitz & Luxenberg Points to Sanofi's Own Words on a Cancer That Hides Behind Eczema
- HeadlineSanofi, Regeneron Expand Immunology Alliance With New Antibodies
- HeadlineRegeneron And Sanofi Announce A Win-Win Collaboration Expansion
- HeadlineRegeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion
- HeadlineSanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion
- HeadlineSanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
- HeadlineRegeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
- HeadlinePress Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
- CongressLisa McClain sold $1,001 - $15,000 of SNY
- CongressLisa McClain bought $1,001 - $15,000 of SNY
- CongressLisa McClain sold $1,001 - $15,000 of SNY
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.